Eli Lilly's drug candidate donanemab treating Alzheimer's disease has received breakthrough therapy status at the US Food and Drug Administration, according to a press release from Eli Lilly.
The coveted designation is given to drug candidates treating serious or life-threatening diseases with preliminary data indicating that this drug can significantly improve treatment opportunities.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.